{"id":2830,"date":"2021-10-25T07:25:44","date_gmt":"2021-10-25T07:25:44","guid":{"rendered":"https:\/\/aceoncology.org\/?p=2830"},"modified":"2021-10-25T07:26:37","modified_gmt":"2021-10-25T07:26:37","slug":"pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma","status":"publish","type":"post","link":"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/","title":{"rendered":"\u5e15\u535a\u5229\u73e0\u5355\u6297\u5bf9\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u6709\u76ca"},"content":{"rendered":"\n<p>\u4f7f\u7528PD-1\u6291\u5236\u5242\uff08<a href=\"https:\/\/www.thelancet.com\/article\/S1470-2045(20)30494-0\/fulltext\">\u7eb3\u6b66\u5229\u5c24\u5355\u6297<\/a>\u6216<a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(21)00065-6\/fulltext\">\u5e15\u535a\u5229\u73e0\u5355\u6297<\/a>\uff09\u4f5c\u4e3a\u53ef\u5207\u9664\u7684III\/IV\u671f\u9ed1\u8272\u7d20\u7624\u7684\u8f85\u52a9\u514d\u75ab\u6cbb\u7597\uff0c\u53ef\u4f7f\u590d\u53d1\u98ce\u9669\u964d\u4f4e\u7ea640%\uff0c\u4e5f\u5df2\u6210\u4e3a\u6807\u51c6\u6cbb\u7597\u3002\u65e0\u6dcb\u5df4\u7ed3\u53d7\u7d2f\u4f46\u539f\u53d1\u7076\u6709\u5305\u62ec\u6d78\u6da6\u6df1\u5ea6\u6216\u6e83\u75a1\uff08\u2161b\u671f\u6216\u2161c\u671f\uff09\u7b49\u9ad8\u5371\u7279\u5f81\u7684\u60a3\u8005\uff0c\u590d\u53d1\u98ce\u9669\u589e\u52a0\uff0c\u9884\u540e\u4e0e\u2162\u671f\u9ed1\u8272\u7d20\u7624\u76f8\u4f3c\u3002\u7136\u800c\uff0c\u76ee\u524d\uff0c\u8f85\u52a9\u6cbb\u7597\u5e76\u4e0d\u662f\u8fd9\u4e9b\u60a3\u8005\u7684\u6807\u51c6\u6cbb\u7597\u3002\u4e0d\u8fc7\uff0c\u8f85\u52a9\u6297PD-1\u6cbb\u7597\u5728III\u671f\u9ed1\u8272\u7d20\u7624\u4e2d\u7684\u7597\u6548\u548c\u53ef\u63a7\u7684\u6bd2\u6027\u7279\u5f81\uff0c\u4e5f\u6709\u5e0c\u671b\u4f7fII\u671f\u60a3\u8005\u83b7\u76ca\u4e8e\u514d\u75ab\u6cbb\u7597\u3002\u76ee\u524dIII\u671f\u4e34\u5e8a\u7814\u7a76\u6b63\u5728\u5bf9\u6b64\u8fdb\u884c\u8bc4\u4f30\u3002<\/p>\n\n\n\n<p>\u57282021\u5e74ESMO\u5927\u4f1a\u4e0a\uff0c\u7f8e\u56fd\u5bbe\u5dde\u5339\u5179\u5821UPMC\u7684\u5e0c\u5c14\u66fc\u764c\u75c7\u4e2d\u5fc3\u7684Jason J. Luke\u535a\u58eb\u516c\u5e03\u4e86III\u671f\u3001\u968f\u673a\u3001\u53cc\u76f2 <a href=\"https:\/\/s3.eu-central-1.amazonaws.com\/m-anage.com.storage.esmo\/static\/esmo2021_abstractsv2\/LBA3.html.pdf\">KEYNOTE-716 \u7814\u7a76<\/a>\u7684\u7ed3\u679c\uff0c\u8be5\u7814\u7a76\u662f\u7b2c\u4e00\u9879\u5728\u53ef\u5207\u9664\u7684IIB\u6216IIC\u671f\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u4e2d\uff0c\u8bc4\u4f30\u5e15\u535a\u5229\u73e0\u5355\u6297\u5bf9\u6bd4\u5b89\u6170\u5242\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u7684\u7814\u7a76\u3002\u7814\u7a76\u5305\u62ec\u8f85\u52a9\u6cbb\u7597\u548c\u518d\u6311\u6218\/\u4ea4\u53c9\u90e8\u5206\u3002\u8bb2\u8005\u4ec5\u6c47\u62a5\u4e86\u8f85\u52a9\u90e8\u5206\u7684\u6570\u636e\uff0c\u5176\u4e2d976\u4f8b\u60a3\u8005\u968f\u673a\u63a5\u53d7\u5e15\u535a\u5229\u73e0\u5355\u6297\u6216\u5b89\u6170\u5242\u6cbb\u7597\uff0c\u6700\u957f\u81f31\u5e74\u3002\u60a3\u8005\u6839\u636eT\u5206\u7ea7\uff083b\u30014a\u548c4b\uff09\u548c\u513f\u7ae5\u72b6\u6001\u8fdb\u884c\u4e86\u5206\u5c42\uff0c\u5c3d\u7ba1\u513f\u7ae5\u60a3\u8005\u7684\u7d2f\u8ba1\u5165\u7ec4\u8f83\u4f4e\u3002\u5728\u4e2d\u4f4d\u968f\u8bbf14\u4e2a\u6708\u65f6\uff0c\u4e24\u7ec4\u5747\u672a\u8fbe\u5230\uff08NR\uff09\u7814\u7a76\u4e3b\u8981\u7ec8\u70b9\u4e2d\u4f4d\u65e0\u590d\u53d1\u751f\u5b58\u671f\uff08RFS\uff09\u300212\u4e2a\u6708\u65f6\uff0c\u5e15\u535a\u5229\u73e0\u5355\u6297\u7ec4\u7684RFS\u7387\u4e3a90.5%\uff0c\u5b89\u6170\u5242\u7ec4\u4e3a83.1%\uff08HR\uff0c0.65\uff1bP = 0.00658\uff09\u3002\u6240\u6709\u4e3b\u8981\u4e9a\u7ec4\u5747\u8bc1\u5b9e\u4e86\u5e15\u535a\u5229\u73e0\u5355\u6297\u7684\u83b7\u76ca\u3002\u5927\u591a\u6570\u60a3\u8005\u4f7f\u7528\u5e15\u535a\u5229\u73e0\u5355\u6297\uff0888.9%\uff09\u6216\u5b89\u6170\u5242\uff0883.2%\uff09\u540e\u65e0\u590d\u53d1\uff0c\u4f46\u5728\u590d\u53d1\u60a3\u8005\u4e2d\uff0c\u5e15\u535a\u5229\u73e0\u5355\u6297\u4f7f\u8fdc\u5904\u590d\u53d1\u7387\u964d\u4f4e\u4e86\u8fd1\u4e00\u534a\uff084.7% vs. 7.8%\uff09\u3002<\/p>\n\n\n\n<p>\u4e0e\u9884\u671f\u76f8\u540c\uff0c\u5e15\u535a\u5229\u73e0\u5355\u6297\u7ec4\uff0893.0%\uff09\u7684\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\uff08TRAE\uff09\u53d1\u751f\u7387\u9ad8\u4e8e\u5b89\u6170\u5242\u7ec4\uff0889.1%\uff09\u3002\u5e15\u535a\u5229\u73e0\u5355\u6297\u8f85\u52a9\u6cbb\u7597\u7684\u5b89\u5168\u6027\u7279\u5f81\u4e0e\u65e2\u5f80\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u89c2\u5bdf\u5230\u7684\u4e00\u81f4\u3002\u5e15\u535a\u5229\u73e0\u5355\u6297\u7ec4\u548c\u5b89\u6170\u5242\u7ec43-4\u7ea7TRAE\u7684\u53d1\u751f\u7387\u5206\u522b\u4e3a16.1%\u548c4.3%\u3002\u6b64\u5916\uff0c\u5e15\u535a\u5229\u73e0\u5355\u6297\u7ec4\u56e0TRAE\u505c\u836f\u7684\u53d1\u751f\u7387\u66f4\u9ad8\uff0815.3% vs. 2.5%\uff09\u3002\u7532\u72b6\u817a\u529f\u80fd\u51cf\u9000\u548c\u7532\u72b6\u817a\u529f\u80fd\u4ea2\u8fdb\u662f\u5e15\u535a\u5229\u73e0\u5355\u6297\u6700\u5e38\u89c1\u7684AE\uff0c\u5927\u591a\u6570\u4e3a1\u7ea7\u62162\u7ea7\u3002\u503c\u5f97\u5173\u6ce8\u7684\u662f\uff0c\u5b89\u6170\u5242\u7ec4\u7532\u72b6\u817a\u76f8\u5173AE\u7684\u53d1\u751f\u7387\u4e5f\u8fbe\u5230\u4e864-5%\u3002\u5e15\u535a\u5229\u73e0\u5355\u6297\u7ec4\u7ea620%\u53d1\u751f\u5185\u5206\u6cccAE\u7684\u60a3\u8005\u9700\u8981\u957f\u671f\u6fc0\u7d20\u6cbb\u7597\u6765\u7ba1\u7406\u5185\u5206\u6ccc\u6bd2\u6027\uff08\u7532\u72b6\u817a\u6bd2\u6027\u4e3a13.9%\uff09\u3002\u7136\u800c\uff0c\u5e15\u535a\u5229\u73e0\u5355\u6297\u6cbb\u7597\u5e76\u672a\u5bf9\u751f\u6d3b\u8d28\u91cf\u4ea7\u751f\u8d1f\u9762\u5f71\u54cd\u3002<\/p>\n\n\n\n<p>Luke\u535a\u58eb\u5f97\u51fa\u7ed3\u8bba\uff0c\u53ef\u5207\u9664\u7684IIB\u548cIIC\u671f\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u65e9\u671f\u590d\u53d1\u7684\u98ce\u9669\u8f83\u9ad8\uff0c\u8f85\u52a9\u5e15\u535a\u5229\u73e0\u5355\u6297\u662f\u4e00\u79cd\u6709\u6548\u7684\u6cbb\u7597\u9009\u62e9\uff0c\u5bf9\u8fd9\u4e9b\u60a3\u8005\u83b7\u76ca\u98ce\u9669\u826f\u597d\u3002\u8be5\u7814\u7a76\u7684\u8ba8\u8bba\u5609\u5bbe\u7f8e\u56fd\u52a0\u5dde\u6d1b\u6749\u77f6Cedars-Sinai\u533b\u5b66\u4e2d\u5fc3&nbsp; Angeles\u4e34\u5e8a\u7814\u7a76\u6240\u7684Omid Hamid\u535a\u58eb\u6307\u51fa\uff0c\u4f7f\u7528\u5e15\u535a\u5229\u73e0\u5355\u6297\u89c2\u5bdf\u5230\u7684\u8fdc\u5904\u590d\u53d1\u663e\u8457\u51cf\u5c11\uff0c\u201c\u8db3\u4ee5\u4f7f\u8be5\u6cbb\u7597\u6210\u4e3a\u5408\u9002\u60a3\u8005\u7684\u6807\u51c6\u6cbb\u7597\u201d\uff0c\u540c\u65f6\u4ecd\u9700\u7b49\u5f85\u672c\u7814\u7a76\u7684\u603b\u751f\u5b58\u671f\u6570\u636e\u3002\u6b64\u5916\uff0c\u4ed6\u5f3a\u8c03\u9700\u8981\u9884\u6d4b\u6027\u751f\u7269\u6807\u5fd7\u7269\u6765\u8bc6\u522b\u90a3\u4e9b\u4f1a\u4ece\u6cbb\u7597\u4e2d\u83b7\u76ca\u7684\u60a3\u8005\uff0c\u540c\u65f6\u907f\u514d\u5bf9\u5176\u4ed6\u60a3\u8005\u4ea7\u751f\u4e0d\u5fc5\u8981\u7684\u6bd2\u6027\u3002\u6b64\u5916\uff0c\u4ed6\u8fd8\u6307\u51fa\u4e86\u76ee\u524d\u6b63\u5728\u8fdb\u884c\u7684\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u7814\u7a76\u7684\u51e0\u4e2a\u95ee\u9898\uff0c\u5305\u62ec\u8bc4\u4f30\u8f85\u52a9\u514d\u75ab\u6cbb\u7597\u5728I\u671f\u9ed1\u8272\u7d20\u7624\u4e2d\u7684\u83b7\u76ca\u3001\u964d\u4f4e\u514d\u75ab\u6cbb\u7597\u7684\u9891\u7387\u548c\u5f3a\u5ea6\u4ee5\u53ca\u75ab\u82d7\u548c\u8f85\u52a9\u8054\u5408\u6cbb\u7597\u5728II\u671f\u75be\u75c5\u4e2d\u7684\u4f5c\u7528\u3002<\/p>\n\n\n\n<p><strong>\u53c2\u8003\u6587\u732e:<\/strong><br>Luke J, et al. <em>ESMO <\/em>2021; Abstract LBA3.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u4f7f\u7528PD-1\u6291\u5236\u5242\uff08\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u6216\u5e15\u535a\u5229\u73e0\u5355\u6297\uff09\u4f5c\u4e3a\u53ef\u5207\u9664\u7684III\/IV\u671f\u9ed1\u8272\u7d20\u7624\u7684\u8f85\u52a9\u514d\u75ab\u6cbb\u7597\uff0c\u53ef\u4f7f\u590d\u53d1\u98ce\u9669 [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":2810,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[78],"tags":[],"class_list":["post-2830","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-78"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u5e15\u535a\u5229\u73e0\u5355\u6297\u5bf9\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u6709\u76ca - ACE Oncology<\/title>\n<meta name=\"description\" content=\"\u5e15\u535a\u5229\u73e0\u5355\u6297\u964d\u4f4e\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u590d\u53d1\u98ce\u9669\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u5e15\u535a\u5229\u73e0\u5355\u6297\u5bf9\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u6709\u76ca - ACE Oncology\" \/>\n<meta property=\"og:description\" content=\"\u5e15\u535a\u5229\u73e0\u5355\u6297\u964d\u4f4e\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u590d\u53d1\u98ce\u9669\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"ACE Oncology\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-25T07:25:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-25T07:26:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/10\/Picture-Blog-Post-63-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"949\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ACE Demo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:site\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ACE Demo\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/\"},\"author\":{\"name\":\"ACE Demo\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0\"},\"headline\":\"\u5e15\u535a\u5229\u73e0\u5355\u6297\u5bf9\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u6709\u76ca\",\"datePublished\":\"2021-10-25T07:25:44+00:00\",\"dateModified\":\"2021-10-25T07:26:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/\"},\"wordCount\":55,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/10\/Picture-Blog-Post-63-scaled.jpg\",\"articleSection\":[\"\u4f1a\u8bae\u901f\u9012\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/\",\"url\":\"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/\",\"name\":\"\u5e15\u535a\u5229\u73e0\u5355\u6297\u5bf9\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u6709\u76ca - ACE Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/10\/Picture-Blog-Post-63-scaled.jpg\",\"datePublished\":\"2021-10-25T07:25:44+00:00\",\"dateModified\":\"2021-10-25T07:26:37+00:00\",\"description\":\"\u5e15\u535a\u5229\u73e0\u5355\u6297\u964d\u4f4e\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u590d\u53d1\u98ce\u9669\",\"breadcrumb\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#primaryimage\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/10\/Picture-Blog-Post-63-scaled.jpg\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/10\/Picture-Blog-Post-63-scaled.jpg\",\"width\":2560,\"height\":949},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"ACE Oncology\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u5e15\u535a\u5229\u73e0\u5355\u6297\u5bf9\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u6709\u76ca\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aceoncology.org\/#website\",\"url\":\"https:\/\/aceoncology.org\/\",\"name\":\"ACE Oncology\",\"description\":\"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.\",\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aceoncology.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aceoncology.org\/#organization\",\"name\":\"ACE Oncology\",\"url\":\"https:\/\/aceoncology.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"width\":156,\"height\":83,\"caption\":\"ACE Oncology\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ace_oncology\",\"https:\/\/www.linkedin.com\/company\/aceoncology\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0\",\"name\":\"ACE Demo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g\",\"caption\":\"ACE Demo\"},\"url\":\"https:\/\/aceoncology.org\/zh-hans\/author\/demo\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u5e15\u535a\u5229\u73e0\u5355\u6297\u5bf9\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u6709\u76ca - ACE Oncology","description":"\u5e15\u535a\u5229\u73e0\u5355\u6297\u964d\u4f4e\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u590d\u53d1\u98ce\u9669","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/","og_locale":"zh_CN","og_type":"article","og_title":"\u5e15\u535a\u5229\u73e0\u5355\u6297\u5bf9\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u6709\u76ca - ACE Oncology","og_description":"\u5e15\u535a\u5229\u73e0\u5355\u6297\u964d\u4f4e\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u590d\u53d1\u98ce\u9669","og_url":"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/","og_site_name":"ACE Oncology","article_published_time":"2021-10-25T07:25:44+00:00","article_modified_time":"2021-10-25T07:26:37+00:00","og_image":[{"width":2560,"height":949,"url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/10\/Picture-Blog-Post-63-scaled.jpg","type":"image\/jpeg"}],"author":"ACE Demo","twitter_card":"summary_large_image","twitter_creator":"@ace_oncology","twitter_site":"@ace_oncology","twitter_misc":{"\u4f5c\u8005":"ACE Demo","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#article","isPartOf":{"@id":"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/"},"author":{"name":"ACE Demo","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0"},"headline":"\u5e15\u535a\u5229\u73e0\u5355\u6297\u5bf9\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u6709\u76ca","datePublished":"2021-10-25T07:25:44+00:00","dateModified":"2021-10-25T07:26:37+00:00","mainEntityOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/"},"wordCount":55,"commentCount":0,"publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/10\/Picture-Blog-Post-63-scaled.jpg","articleSection":["\u4f1a\u8bae\u901f\u9012"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/","url":"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/","name":"\u5e15\u535a\u5229\u73e0\u5355\u6297\u5bf9\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u6709\u76ca - ACE Oncology","isPartOf":{"@id":"https:\/\/aceoncology.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#primaryimage"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/10\/Picture-Blog-Post-63-scaled.jpg","datePublished":"2021-10-25T07:25:44+00:00","dateModified":"2021-10-25T07:26:37+00:00","description":"\u5e15\u535a\u5229\u73e0\u5355\u6297\u964d\u4f4e\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u590d\u53d1\u98ce\u9669","breadcrumb":{"@id":"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#primaryimage","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/10\/Picture-Blog-Post-63-scaled.jpg","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/10\/Picture-Blog-Post-63-scaled.jpg","width":2560,"height":949},{"@type":"BreadcrumbList","@id":"https:\/\/aceoncology.org\/zh-hans\/pembrolizumab-reduces-risk-of-recurrence-in-high-risk-stage-ii-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"ACE Oncology","item":"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/"},{"@type":"ListItem","position":2,"name":"\u5e15\u535a\u5229\u73e0\u5355\u6297\u5bf9\u9ad8\u98ce\u9669II\u671f\u9ed1\u8272\u7d20\u7624\u6709\u76ca"}]},{"@type":"WebSite","@id":"https:\/\/aceoncology.org\/#website","url":"https:\/\/aceoncology.org\/","name":"ACE Oncology","description":"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.","publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aceoncology.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/aceoncology.org\/#organization","name":"ACE Oncology","url":"https:\/\/aceoncology.org\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","width":156,"height":83,"caption":"ACE Oncology"},"image":{"@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ace_oncology","https:\/\/www.linkedin.com\/company\/aceoncology"]},{"@type":"Person","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0","name":"ACE Demo","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g","caption":"ACE Demo"},"url":"https:\/\/aceoncology.org\/zh-hans\/author\/demo\/"}]}},"_links":{"self":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/2830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/comments?post=2830"}],"version-history":[{"count":3,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/2830\/revisions"}],"predecessor-version":[{"id":2833,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/2830\/revisions\/2833"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media\/2810"}],"wp:attachment":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media?parent=2830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/categories?post=2830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/tags?post=2830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}